Literature DB >> 21632553

Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.

Cenap Güngör1, Hilke Zander, Katharina E Effenberger, Yogesh K Vashist, Tatyana Kalinina, Jakob R Izbicki, Emre Yekebas, Maximilian Bockhorn.   

Abstract

The incidence of pancreatic ductal adenocarcinoma (PDAC) nearly equals its mortality rate, partly because most PDACs are intrinsically chemoresistant and thus largely untreatable. It was found recently that chemoresistant PDAC cells overexpress the Notch-2 receptor and have undergone epithelial-mesenchymal transition (EMT). In this study, we show that these two phenotypes are interrelated by expression of Midkine (MK), a heparin-binding growth factor that is widely overexpressed in chemoresistant PDAC. Gemcitabine, the front-line chemotherapy used in PDAC treatment, induced MK expression in a dose-dependent manner, and its RNAi-mediated depletion was associated with sensitization to gemcitabine treatment. We identified an interaction between the Notch-2 receptor and MK in PDAC cells. MK-Notch-2 interaction activated Notch signaling, induced EMT, upregulated NF-κB, and increased chemoresistance. Taken together, our findings define an important pathway of chemoresistance in PDAC and suggest novel strategies for its clinical attack. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21632553     DOI: 10.1158/0008-5472.CAN-11-0036

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

1.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

2.  Twist1 is a potential prognostic marker for colorectal cancer and associated with chemoresistance.

Authors:  Da-Jian Zhu; Xiao-Wu Chen; Wei-Jie Zhang; Jia-Zhi Wang; Man-Zhao Ouyang; Qiang Zhong; Chang-Chun Liu
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

Review 3.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

4.  Notch-1-mediated esophageal carcinoma EC-9706 cell invasion and metastasis by inducing epithelial-mesenchymal transition through Snail.

Authors:  Tao Wang; Xiaoyan Xuan; Linping Pian; Ping Gao; Hong Hu; Yuling Zheng; Wenqiao Zang; Guoqiang Zhao
Journal:  Tumour Biol       Date:  2014-02

5.  Notch Signaling Pathway in Pancreatic Cancer Progression.

Authors:  Jia Ma; Jun Xia; Lucio Miele; Fazlul H Sarkar; Zhiwei Wang
Journal:  Pancreat Disord Ther       Date:  2013-05-30

Review 6.  Pancreatic cancer.

Authors:  C Güngör; B T Hofmann; G Wolters-Eisfeld; M Bockhorn
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 7.  Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

Authors:  Ying Zeng; Agnieszka A Rucki; Xu Che; Lei Zheng
Journal:  J Gastrointest Oncol       Date:  2017-06

8.  RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.

Authors:  Xin-Xiang Li; Jun-Jie Peng; Lei Liang; Li-Yong Huang; Da-Wei Li; De-Bing Shi; Hong-Tu Zheng; San-Jun Cai
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

9.  Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.

Authors:  Betty K Samulitis; Kelvin W Pond; Erika Pond; Anne E Cress; Hitendra Patel; Lee Wisner; Charmi Patel; Robert T Dorr; Terry H Landowski
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

10.  CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.

Authors:  Lei Yin; Shuai Liu; Chensheng Li; Sentai Ding; Dongbin Bi; Zhihong Niu; Liping Han; Wenjia Li; Dexuan Gao; Zheng Liu; Jiaju Lu
Journal:  Tumour Biol       Date:  2016-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.